KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib - Smith, John C.; Brooks, Laura; Hoff, Paulo M.; McWalter, Gael; Dearden, Simon; Morgan, Shethah R.; Wilson, David; Robertson, Jane D.; Jürgensmeier, Juliane M. (European Journal of Cancer, 2013)